Melatonin mini-tablets and method of manufacturing the same

Inventors

Laudon, Moshe • Zisapel, Nava

Assignees

Neurim Pharmaceuticals 1991 Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10722494-B2

Patent

Publication Date

2020-07-28

Expiration Date


Abstract

The instant invention is generally directed to a patient-friendly drug delivery system for targeted populations, such as pediatric and geriatric patients. Specifically, the present invention relates to a pharmaceutical composition in the form of mini-tablets. Even more specifically, the present invention relates to a pharmaceutical composition comprising a therapeutically-effective amount of melatonin in the form of mini-tablets.

Core Innovation

The disclosure addresses controlled-release melatonin mini-tablet formulations having a diameter less than or equal to 4 mm for pediatric, geriatric, and dysphagia patient populations, where larger tablets may present compliance issues. The mini-tablets are intended to induce sleep and to provide a release profile suited to oral ingestion by a human patient.

The invention defines quantitative performance and release behavior for the controlled-release mini-tablets, including a melatonin release of less than 50% within 1 hour and about greater than 70% within 6 hours after oral ingestion. It further describes minimal melatonin blood levels of about 60 to 200 pg/mL over at least four hours as a performance target, and characterizes the resulting melatonin exposure as substantially simulating a normal endogenous melatonin plasma profile.

The mini-tablet formulations contain 1 mg or 5 mg melatonin with one or more pharmaceutically acceptable carriers, and include ammonio methacrylate copolymer, calcium hydrogen phosphate dihydrate, and lactose monohydrate. A weight ratio between melatonin, ammonio methacrylate copolymer, calcium hydrogen phosphate dihydrate, and lactose monohydrate is defined in the range 1:1.1-5.9:0.8-8.3:1.8-8.8, with options for specific polymer types and for additional excipients and coatings.

Claims Coverage

The partial content provides two independent claims: one directed to a controlled-release melatonin mini-tablet with a defined diameter and in vivo release profile, and a second directed to a mini-tablet formulation designed to substantially simulate a normal endogenous melatonin plasma profile. Across these independent claims, the inventive coverage centers on the small mini-tablet size, the defined release/plasma-response performance, and the specified formulation components with a defined melatonin-to-excipient weight ratio.

Controlled-release melatonin mini-tablet with defined size and in vivo release profile

A controlled-release melatonin mini-tablet comprising 1 mg or 5 mg melatonin and one or more pharmaceutically acceptable carriers, wherein the mini-tablet has a diameter less than or equal to 4 mm and has a release profile of less than 50% melatonin release within 1 hour and about greater than 70% melatonin release within 6 hours of oral ingestion by a human patient.

Defined formulation composition with melatonin-to-excipient weight ratio

The mini-tablet contains ammonio methacrylate copolymer, calcium hydrogen phosphate dihydrate, and lactose monohydrate, wherein the ratio between melatonin, ammonio methacrylate copolymer, calcium hydrogen phosphate dihydrate and lactose monohydrate by weight is 1:1.1-5.9:0.8-8.3:1.8-8.8.

Mini-tablet formulation substantially simulating normal endogenous melatonin plasma profile

A pharmaceutical mini-tablet formulation comprising 1 mg or 5 mg melatonin in combination with at least one pharmaceutical carrier, diluent or coating, wherein, upon administration to a patient, the mini-tablet formulation releases melatonin over time such that the patient's melatonin plasma profile substantially simulates the melatonin plasma profile of a human having a normal endogenous melatonin profile.

Taken together, the independent claims require a controlled-release melatonin mini-tablet of very small diameter with specified early and later melatonin release behavior, and a mini-tablet formulation that is designed so the patient melatonin plasma profile substantially simulates a normal endogenous profile. Both independent claims further require the same core formulation components—ammonio methacrylate copolymer, calcium hydrogen phosphate dihydrate, and lactose monohydrate—with a defined melatonin-to-component weight ratio.

Stated Advantages

Enables a melatonin release over time such that the patient's melatonin plasma profile substantially simulates the melatonin plasma profile of a human having a normal endogenous melatonin profile.

Provides a mini-tablet with a diameter less than or equal to 4 mm suitable for pediatric, geriatric, and dysphagia patient populations.

Induces sleep as described for the mini-tablets.

Documented Applications

Pediatric patients (2–18 years) and geriatric patients (>65 years) as described in the context of melatonin mini-tablet use for compliance and administration.

Dysphagia patient populations as described in connection with mini-tablet administration.

ASD and neurogenetic diseases in children, supported by a human clinical trial showing improvements versus placebo.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.